2022
A stated preference survey to explore patient preferences for novel preventive migraine treatments
Hubig L, Smith T, Chua G, Lloyd A, Powell L, Johnston K, Harris L, L'Italien G, Coric V, Lo S. A stated preference survey to explore patient preferences for novel preventive migraine treatments. Headache The Journal Of Head And Face Pain 2022, 62: 1187-1197. PMID: 36047857, PMCID: PMC9826196, DOI: 10.1111/head.14386.Peer-Reviewed Original ResearchConceptsPatient preferencesTreatment effectivenessCGRP inhibitorsMigraine frequencyMigraine severityPreventive treatmentOral tabletsSemi-structured patient interviewsOnline discrete choice experiment surveyCalcitonin gene-related peptide (CGRP) inhibitorsPreventive migraine treatmentMonoclonal antibody treatmentSeverity of migraineMode of administrationDiscrete choice experiment surveyHypothetical treatment choicesQuarterly injectionsMonthly injectionsOral therapyAntibody treatmentMigraine treatmentPrescribing choicesPatient interviewsSubgroup analysisTreatment preferences
2020
Assessing Effects of BHV-0223 40 mg Zydis Sublingual Formulation and Riluzole 50 mg Oral Tablet on Liver Function Test Parameters Utilizing DILIsym
Longo D, Shoda L, Howell B, Coric V, Berman R, Qureshi I. Assessing Effects of BHV-0223 40 mg Zydis Sublingual Formulation and Riluzole 50 mg Oral Tablet on Liver Function Test Parameters Utilizing DILIsym. Toxicological Sciences 2020, 175: 292-300. PMID: 32040174, PMCID: PMC7253195, DOI: 10.1093/toxsci/kfaa019.Peer-Reviewed Original ResearchConceptsOral tabletsALT elevationLiver toxicityClinical dataFirst-pass liver metabolismLiver function test parametersFirst-pass hepatic metabolismLiver toxicity riskAlanine transaminase levelsRelative risk reductionLower overall doseAmyotrophic lateral sclerosisALT levelsTransaminase levelsLiver exposureSublingual formulationHepatic metabolismLateral sclerosisRiluzoleLiver metabolismULNInterindividual variabilityOverall doseHepatotoxicity potentialOxidative stress
2019
A Phase 1 Study to Evaluate Bioequivalence Between BHV-0223 40 mg Zydis® Sublingual Formulation and Riluzole 50 mg Oral Tablet in Healthy Volunteers (S5.005)
Qureshi I, Coric V, Gentile K, Larouche R, Tanguay M, Berman R. A Phase 1 Study to Evaluate Bioequivalence Between BHV-0223 40 mg Zydis® Sublingual Formulation and Riluzole 50 mg Oral Tablet in Healthy Volunteers (S5.005). Neurology 2019, 92 DOI: 10.1212/wnl.92.15_supplement.s5.005.Peer-Reviewed Original Research